Physician profile
Howard Williams
NPI 1548210081
$12,610.24
in general payments reported to CMS, 2019-2025
75 companies · $1,846 in 2025
The $1,846 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,682 · 2020: $1,664 · 2021: $1,981 · 2022: $1,738 · 2023: $1,922 · 2024: $1,778 · 2025: $1,846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,545.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,927.15 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $926.78 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novartis Pharmaceuticals Corporation | $817.02 | 2019-2025 | |
| Lilly USA, LLC | $738.11 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Gilead Sciences, INC. | $720.93 | 2019-2025 | |
| Glaxosmithkline, LLC. | $696.31 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $674.61 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $622.30 | 2019-2025 | Evenity, Prolia, Prolia |
| Pfizer INC. | $595.99 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $557.19 | 2019-2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $375.43 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $268.23 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Astellas Pharma US INC | $196.11 | 2019-2024 | Veozah |
| Allergan, INC. | $194.60 | 2019-2020 | |
| Amarin Pharma, INC. | $158.23 | 2019-2022 |
Show all 75 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.